Breakthrough Therapies in Rare Diseases – Tepezza Case Study
Breakthrough therapies are revolutionizing healthcare, particularly for patients with rare diseases. This cohort is nearly 50% larger than the 2022 approval class, which fell below the approval trend line. The average number of new drug approvals by the CDER has climbed to a 20-year high, reaching 46 per year over the past decade. One such […]
Breakthrough Therapies in Rare Diseases – Tepezza Case Study Read More »